Overall, present and previous data envisage the in vivo preclinical studies with hNGF1–14 peptides as potent and selective NGF mimetics, and TrkA agonists for CNS and PNS in age-related or inflammation-driven human neurodegenerative diseases. The gene discussed is NGF; the disease is neurodegenerative disease.